Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia.
- Author:
Ji Hyung HONG
1
;
Sung Eun LEE
;
Soo Young CHOI
;
Soo Hyun KIM
;
Eun Jung JANG
;
Ju Hee BANG
;
Jin Eok PARK
;
Hye Rim JEON
;
Yun Jeong OH
;
Jeong Eun YI
;
Hae Ok JUNG
;
Ho Joong YOUN
;
Dong Wook KIM
Author Information
- Publication Type:Case Report
- Keywords: Dasatinib; Pulmonary arterial hypertension; Chronic myeloid leukemia
- MeSH: Blood Pressure; Dyspnea; Echocardiography, Doppler; Follow-Up Studies; Heart; Humans; Hypertension*; Leukemia, Myelogenous, Chronic, BCR-ABL Positive*; Protein-Tyrosine Kinases
- From:Cancer Research and Treatment 2015;47(4):937-942
- CountryRepublic of Korea
- Language:English
- Abstract: We describe two cases of pulmonary arterial hypertension (PAH) that occurred under dasatinib treatment and were resolved after dasatinib discontinuation. Two patients with chronic phase chronic myeloid leukemia (CML) were switched to dasatinib therapy because of hematological progress while receiving imatinib. These patients had New York Heart Association (NYHA) functional class II dyspnea with elevated right ventricular systolic pressure (RVSP), which progressed under dasatinib treatment. After dasatinib treatment was discontinued, subjective symptoms were improved to NYHA functional class I and the follow-up transthoracic Doppler echocardiography showed improved RVSP. Treatment with an alternate tyrosine kinase inhibitor was initiated and had been continued without development of dyspnea or elevation of RVSP. This report suggests that dasatinib can cause the reversible PAH, therefore, routine cardiopulmonary evaluation before and during treatment with dasatinib may be needed in CML patients with clinical manifestations.
